Edition:
United States

Biotechnology & Medical Research

Page 1

AMYGDALA NEUROSCIENCES ACQUIRES GS-6637 FROM GILEAD SCIENCES

Thursday, 16 Feb 2017 10:03am EST

Amygdala Neurosciences: AMYGDALA NEUROSCIENCES ACQUIRES GS-6637 FROM GILEAD SCIENCES .AMYGDALA NEUROSCIENCES SAYS "IN 2017, LOOK FORWARD TO INITIATING CLINICAL TRIALS FOR TREATMENT OF BOTH COCAINE AND ALCOHOL USE DISORDERS" FOR GS-6637.

Xoma Corp to sell 1.2 mln shares to Biotechnology Value Fund

Monday, 13 Feb 2017 07:00am EST

Xoma Corp : Xoma announces pricing of $25 million registered offering of common stock and convertible preferred stock .Xoma Corp - has agreed to sell 1,200,000 shares of its common stock and 5,003 shares of convertible preferred stock directly to Biotechnology Value Fund.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary